steglatro
merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic acid - diabetes mellitus, tip 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro huwa indikat f'adulti ta '18-il sena u akbar b'dijabete mellitus tip 2 bħala żieda mad-dieta u l-eżerċizzju biex itejjeb il-kontroll gliċemiku:bħala monoterapija f'pazjenti li għalihom l-użu ta' metformin huwa kkunsidrat xieraq minħabba 'intolleranza jew ta' kontra-indikazzjonijiet. barra minn hekk oħra prodotti mediċinali għall-kura tad-dijabete.
rubraca
pharmaand gmbh - rucaparib camsylate - neoplażmi fl-ovarji - aġenti antineoplastiċi - rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (figo stages iii and iv) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. rubraca huwa indikat bħala monoterapija għall-kura ta 'manteniment ta' pazjenti adulti b'sensittiva għall-platinum rkadew grad għoli ta 'l-epitilju ta' l-ovarji, l-tubu fallopjan, jew primarja peritoneali-kanċer li huma fir-rispons (sħiħa jew parzjali) ' kimoterapija bbażata fuq platinum.
kesimpta
novartis ireland ltd - ofatumumab - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosuppressant - kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features (see section 5.
verquvo
bayer ag - vericiguat - insuffiċjenza tal-qalb - terapija kardijaka - treatment of symptomatic chronic heart failure.
voxzogo
biomarin international limited - vosoritide - achondroplasia - drogi għat-trattament ta 'mard tal-għadam - voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. the diagnosis of achondroplasia should be confirmed by appropriate genetic testing.
xenpozyme
sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - oħra tal-passaġġ alimentari u tal-metaboliżmu-prodotti, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.
vyvgart
argenx - efgartigimod alfa - myasthenia gravis - immunosoppressanti - vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gmg) who are anti acetylcholine receptor (achr) antibody positive.
adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)
glaxosmithkline biologicals s.a. - virus tal-influwenza maqsuma, inattivat, li fih antiġen: razza użata bħala a / vietnam / 1194/2004 (h5n1) użata (nibrg-14) - influenza, human; immunization; disease outbreaks - vaċċini - profilassi tal-influwenza f'sitwazzjoni pandemika ddikjarata uffiċjalment. il-vaċċin kontra l-influwenza pandemika għandu jintuża skond il-gwida uffiċjali.
agenerase
glaxo group ltd. - amprenavir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - agenerase, flimkien ma 'mediċini antiretrovirali oħra, huwa indikat għall-kura ta' impeditur protease (pi) b'esperjenza ta 'adulti infettati bl-hiv-1 u tfal' l fuq minn 4 snin. il-kapsuli ta 'agenerase għandhom normalment jiġu amministrati b'doża baxxa ta' ritonavir bħala stimulant farmakokinetiku ta 'amprenavir (ara sezzjonijiet 4. 2 u 4. l-għażla ta 'amprenavir għandha tkun ibbażata fuq ittestjar ta' reżistenza virali individwali u l-istorja tal-kura tal-pazjenti (ara sezzjoni 5. il-benefiċċju ta 'agenerase ma' ritonavir ma ntwerewx f'pi nave-pazjenti (ara sezzjoni 5.
airexar spiromax
teva b.v. - salmeterol, fluticasone propionate - pulmonary disease, chronic obstructive; asthma - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - airexar spiromax huwa indikat għall-użu fl-adulti li għandhom 18-il sena 'l fuq biss. asthmaairexar spiromax is indicated for the regular treatment of patients with severe asthma where use of a combination product (inhaled corticosteroid and long-acting β2 agonist) is appropriate:- patients not adequately controlled on a lower strength corticosteroid combination productor- patients already controlled on a high dose inhaled corticosteroid and long-acting β2 agonist. mard pulmonari ostruttiv kroniku (copd)airexar spiromax huwa indikat għall-kura sintomatika ta ' pazjenti b'copd, bil-fev1.